The effect of sequential therapy with lansoprazole and ecabet sodium in treating iatrogenic gastric ulcer after endoscopic submucosal dissection: A randomized prospective study. Issue 2 (February 2015)

• Record Type: Journal Article
• Authors: Ahn, Ji Yong; Choi, Chang Hwan; Lee, Jang Wook; Park, Sung Jin; Kim, Jeong Wook; Chang, Sae Kyung; Han, Seung Bong
• Is Part Of: Journal of digestive diseases. Volume 16:Issue 2(2015:Feb.)
• Page Start: 75
• Page End: 82
• Publication Date: 2015-02
• Subjects: Digestive organs -- Diseases -- Periodicals; Gastroenterology -- Periodicals; 616.3
• DOI: 10.1111/1751-2980.12214
• Languages: English
• ISSNs: 1751-2972

Abstract

<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="cdd12214-sec-0001" sec-type="section"> <title>Objective</title> <p>Ecabet sodium (ES) is a new non‐systemic anti‐ulcer agent belonging to the category of gastroprotective agents. In this study we aimed to compare the efficacy of a combination therapy with lansoprazole (LS) followed by ES with LS alone in treating endoscopic submucosal dissection (ESD)‐induced iatrogenic gastric ulcers.</p> </sec> <sec id="cdd12214-sec-0002" sec-type="section"> <title>Methods</title> <p>Patients diagnosed with gastric adenomas or early gastric cancer were randomly divided into either the LS group (30 mg once daily for 4 weeks; <italic>n</italic> = 45) or the LS + ES group (LS 30 mg once daily for one week followed by ES 1500 mg twice daily for 3 weeks; <italic>n</italic> = 45). Four weeks after ESD, a follow‐up endoscopy was conducted to evaluate the proportions of ulcer reduction and ulcer stages in the two groups.</p> </sec> <sec id="cdd12214-sec-0003" sec-type="section"> <title>Results</title> <p>In all, 79 patients were included in the final analyses. Both treatment modalities were well‐tolerated in most patients, with a drug compliance of over 80%. There were no significant differences between the two groups in terms of the proportions of ulcer reduction (0.9503 ± 0.1215 in the LS group <italic>vs</italic> 0.9192 ± 0.0700 in the LS + ES group, <italic>P</italic> = 0.169) or ulcer stage (<italic>P</italic> = 0.446). The prevalence of adverse events related to drugs and bleeding were also similar between the two groups.</p> </sec> <sec id="cdd12214-sec-0004" sec-type="section"> <title>Conclusion</title> <p>Sequential therapy with LS + ES is as effective as LS alone against ESD‐induced gastric ulcers.</p> </sec> </abstract>